Ajanta Pharma has officially clarified that it has not considered purchasing shares in Restaurant Brands Asia, according to Reuters reports. The pharmaceutical company's statement addresses any market speculation regarding potential investment interest in the restaurant chain operator.

Official Company Statement

The clarification from Ajanta Pharma comes as a direct response to market queries about potential acquisition interest. The company has explicitly stated that it has not looked into buying shares in Restaurant Brands Asia, putting to rest any speculation about cross-sector investment plans.

Market Implications

This official statement provides clarity to investors and market participants about Ajanta Pharma's current investment strategy. The pharmaceutical company's focus appears to remain within its core business areas rather than diversifying into the restaurant and food service sector.

The statement helps eliminate any uncertainty in the market regarding potential corporate actions between these two companies operating in different sectors.

Ajanta Pharma Limited has announced the incorporation of a wholly owned subsidiary in Ireland, marking a strategic expansion of its pharmaceutical operations. The company disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, on January 13, 2026.

Subsidiary Formation Details

The newly formed entity, named 'Ajanta Pharma Ireland Ltd.,' has been incorporated in Ireland as a wholly owned subsidiary of Ajanta Pharma Limited. The subsidiary has been established specifically for carrying on the business of pharmaceutical products, which aligns with the parent company's core operations in the pharmaceutical industry.

Regulatory Compliance

The formation of this subsidiary was communicated to both the BSE Limited and the National Stock Exchange of India Limited in compliance with regulatory requirements. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, ensuring transparency with stakeholders and regulatory authorities.

Strategic Implications

The establishment of Ajanta Pharma Ireland Ltd. represents the company's continued focus on expanding its pharmaceutical business operations internationally. As a newly incorporated entity, the subsidiary is positioned to support the company's pharmaceutical product business in the Irish market and potentially serve as a strategic base for European operations.

The subsidiary formation does not involve any acquisition costs or share swap arrangements, as it represents a greenfield establishment. No governmental or regulatory approvals were required for this incorporation, and the process has been completed as disclosed to the stock exchanges.